Address Talkabouturology, Nizhny Novgorod, Russia
Skype ukitcom
                                    Talk about urology
Back to the list

Adjuvant Immunotherapy? Nivolumab may be the first immune checkpoint inhibitor indicated for adjuvant use in patients with urothelial cancer, a matter that the FDA is already prioritizing. Detailed data are presented in the current issue of the journal "Oncourology".